Cargando…
A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Type 2 innate lymphoid cells (ILC2s, nuocytes, NHC) require RORA and GATA3 for their development. We show that human ILC2s express skin homing receptors and infiltrate the skin after allergen challenge, where they produce the type 2 cytokines IL-5 and IL-13. Skin-derived ILC2s express the IL-33 rece...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865470/ https://www.ncbi.nlm.nih.gov/pubmed/24323357 http://dx.doi.org/10.1084/jem.20130351 |
_version_ | 1782296043353800704 |
---|---|
author | Salimi, Maryam Barlow, Jillian L. Saunders, Sean P. Xue, Luzheng Gutowska-Owsiak, Danuta Wang, Xinwen Huang, Li-Chieh Johnson, David Scanlon, Seth T. McKenzie, Andrew N.J. Fallon, Padraic G. Ogg, Graham S. |
author_facet | Salimi, Maryam Barlow, Jillian L. Saunders, Sean P. Xue, Luzheng Gutowska-Owsiak, Danuta Wang, Xinwen Huang, Li-Chieh Johnson, David Scanlon, Seth T. McKenzie, Andrew N.J. Fallon, Padraic G. Ogg, Graham S. |
author_sort | Salimi, Maryam |
collection | PubMed |
description | Type 2 innate lymphoid cells (ILC2s, nuocytes, NHC) require RORA and GATA3 for their development. We show that human ILC2s express skin homing receptors and infiltrate the skin after allergen challenge, where they produce the type 2 cytokines IL-5 and IL-13. Skin-derived ILC2s express the IL-33 receptor ST2, which is up-regulated during activation, and are enriched in lesional skin biopsies from atopic patients. Signaling via IL-33 induces type 2 cytokine and amphiregulin expression, and increases ILC2 migration. Furthermore, we demonstrate that E-cadherin ligation on human ILC2 dramatically inhibits IL-5 and IL-13 production. Interestingly, down-regulation of E-cadherin is characteristic of filaggrin insufficiency, a cardinal feature of atopic dermatitis (AD). ILC2 may contribute to increases in type 2 cytokine production in the absence of the suppressive E-cadherin ligation through this novel mechanism of barrier sensing. Using Rag1(−/−) and RORα-deficient mice, we confirm that ILC2s are present in mouse skin and promote AD-like inflammation. IL-25 and IL-33 are the predominant ILC2-inducing cytokines in this model. The presence of ILC2s in skin, and their production of type 2 cytokines in response to IL-33, identifies a role for ILC2s in the pathogenesis of cutaneous atopic disease. |
format | Online Article Text |
id | pubmed-3865470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38654702014-06-16 A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis Salimi, Maryam Barlow, Jillian L. Saunders, Sean P. Xue, Luzheng Gutowska-Owsiak, Danuta Wang, Xinwen Huang, Li-Chieh Johnson, David Scanlon, Seth T. McKenzie, Andrew N.J. Fallon, Padraic G. Ogg, Graham S. J Exp Med Article Type 2 innate lymphoid cells (ILC2s, nuocytes, NHC) require RORA and GATA3 for their development. We show that human ILC2s express skin homing receptors and infiltrate the skin after allergen challenge, where they produce the type 2 cytokines IL-5 and IL-13. Skin-derived ILC2s express the IL-33 receptor ST2, which is up-regulated during activation, and are enriched in lesional skin biopsies from atopic patients. Signaling via IL-33 induces type 2 cytokine and amphiregulin expression, and increases ILC2 migration. Furthermore, we demonstrate that E-cadherin ligation on human ILC2 dramatically inhibits IL-5 and IL-13 production. Interestingly, down-regulation of E-cadherin is characteristic of filaggrin insufficiency, a cardinal feature of atopic dermatitis (AD). ILC2 may contribute to increases in type 2 cytokine production in the absence of the suppressive E-cadherin ligation through this novel mechanism of barrier sensing. Using Rag1(−/−) and RORα-deficient mice, we confirm that ILC2s are present in mouse skin and promote AD-like inflammation. IL-25 and IL-33 are the predominant ILC2-inducing cytokines in this model. The presence of ILC2s in skin, and their production of type 2 cytokines in response to IL-33, identifies a role for ILC2s in the pathogenesis of cutaneous atopic disease. The Rockefeller University Press 2013-12-16 /pmc/articles/PMC3865470/ /pubmed/24323357 http://dx.doi.org/10.1084/jem.20130351 Text en © 2013 Salimi et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Article Salimi, Maryam Barlow, Jillian L. Saunders, Sean P. Xue, Luzheng Gutowska-Owsiak, Danuta Wang, Xinwen Huang, Li-Chieh Johnson, David Scanlon, Seth T. McKenzie, Andrew N.J. Fallon, Padraic G. Ogg, Graham S. A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis |
title | A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis |
title_full | A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis |
title_fullStr | A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis |
title_full_unstemmed | A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis |
title_short | A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis |
title_sort | role for il-25 and il-33–driven type-2 innate lymphoid cells in atopic dermatitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865470/ https://www.ncbi.nlm.nih.gov/pubmed/24323357 http://dx.doi.org/10.1084/jem.20130351 |
work_keys_str_mv | AT salimimaryam aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT barlowjillianl aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT saundersseanp aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT xueluzheng aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT gutowskaowsiakdanuta aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT wangxinwen aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT huanglichieh aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT johnsondavid aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT scanlonsetht aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT mckenzieandrewnj aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT fallonpadraicg aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT ogggrahams aroleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT salimimaryam roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT barlowjillianl roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT saundersseanp roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT xueluzheng roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT gutowskaowsiakdanuta roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT wangxinwen roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT huanglichieh roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT johnsondavid roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT scanlonsetht roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT mckenzieandrewnj roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT fallonpadraicg roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis AT ogggrahams roleforil25andil33driventype2innatelymphoidcellsinatopicdermatitis |